Introduction In January 2025, the National Institutes of Health (NIH) introduced a new NIH Intramural Research Program Access Planning Policy (“IRP Access Planning Policy” or “Policy”). An NIH web page provides links to several documents describing the policy: https://osp.od.nih.gov/policies/innovation-and-translation#tab1/ The… Continue Reading
KEI-NIH-T-Cure-Biosciences22Oct2024 Knowledge Ecology International (KEI) objects to the “Prospective Grant of an Exclusive Patent License: Anti-KK-LC-1 T Cell Receptors” (89 FR 81089) to T-Cure Biosciences, Inc. (T-Cure). Among other things, KEI said the NIH needs to be more forthcoming in… Continue Reading
KEI2HHS19Sep2024 September 19, 2024 Emily Bleimund, JD, MA Director, Office of Trade and Health U.S. Department of Health and Human Services Steven T. Smith National Institute of Allergy and Infectious Diseases (NIAID) Representative, Geneva, Switzerland Dear Emily and Steven, I… Continue Reading
The USPTO has a request for comment on the need for a statutory experimental use exception for patents. (89 FR 53963). The USPTO uploads the comments to Regulations.Gov, docket PTO-C-2024-0023. KEI filed comments on September 10, 2024: KEI-Experimental-use-exception-10Sept2024 September 10,… Continue Reading
The PDF version of the letter has all tables and footnotes: KEI-NIH-28Aug2028 August 28, 2024 Abby Rives, JD Division Director Technology Transfer and Innovation Policy National Institutes for Health Vladimir Knezevic, MD Senior Advisor for Commercial Evaluation Technology Advancement Office… Continue Reading
In a notice to the federal register, the NIH is announcing a new policy to address issues of access and equity in the licensing of NIH patented inventions. (The Federal Register notice is here. Secretary Becerra announcement is here). The… Continue Reading